Table 1.
A review on COVID-19 peptide-based vaccines: clinical studies
| Study name | Phase of clinical trial | Peptide design | Adjuvants | References |
|---|---|---|---|---|
| P-pVAC-SARS-CoV-2 | I | SARS-CoV-2 specific HLA class II peptides | Montanide ISA 51 VG and TLR1/2 ligand XS15 | University Hospital Tuebingen. (2021a) |
| B-pVAC-SARS-CoV-2 | I/II | SARS-CoV-2-derived multi-peptide vaccine | TLR1/2 ligand XS15 | University Hospital Tuebingen. (2021b) |
| EpiVacCorona Peptide Antigen-based Vaccine | III–IV | SARS-CoV-2 proteins conjugated to a carrier protein | Aluminum-containing adjuvant | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector.” (2021) |
| UB-612 Vaccine | I | S1-RBD protein-based vaccine incorporating a Th/CTL epitope peptide pool | – | United Biomedical Inc. 2021) |
| COVEPIT-3:OSE-13E | I | CoVepiT vaccine—against 11 proteins of the SARS-CoV-2 virus | – | OSE Immunotherapeutics (2021) |